Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination

Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer

(2011) L. Arnheim Dahlstrom et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Serotype replacement in disease after pneumococcal vaccination

(2011) Daniel M Weinberger et al.   LANCET

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia

(2011) Megan A. Smith et al.   VACCINE

Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women

(2010) R. P. Insinga et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33

(2010) Marko Merikukka et al.   INTERNATIONAL JOURNAL OF CANCER

Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007–2008

(2010) La'Shan D. Taylor et al.   PREVENTIVE MEDICINE

Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women

(2009) Marjo Kaasila et al.   INTERNATIONAL JOURNAL OF CANCER

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

A review of human carcinogens—Part B: biological agents

(2009) Véronique Bouvard et al.   LANCET ONCOLOGY

Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study

(2008) Loretta Brabin et al.   BMJ-British Medical Journal